Abeona Therapeutics Inc. (ABEO)
| Market Cap | 66.25M |
| Revenue (ttm) | 3.00M |
| Net Income (ttm) | -54.08M |
| Shares Out | 101.92M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 559,100 |
| Open | 0.640 |
| Previous Close | 0.634 |
| Day's Range | 0.620 - 0.662 |
| 52-Week Range | 0.560 - 3.790 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+669.2%) |
| Earnings Date | Nov 15, 2021 |
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for th...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price forecast is 5.00, which is an increase of 669.23% from the latest price.
News
Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround
Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...
Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Ed...
NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second annua...
Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conf...
NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the company'...
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Ex...
Abeona Therapeutics Reports Third Quarter Financial Results
Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., ...
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously dis...
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice...
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Bi...
Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board
Abeona Therapeutics to Present at Upcoming Investor Conferences
NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company's mana...
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as C...
Abeona Therapeutics Reports Second Quarter Financial Results
Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study
Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy
Abeona Therapeutics Inc (NASDAQ: ABEO) has completed a Type B meeting with the FDA regarding the pivotal trial for its ABO-102 gene therapy for Sanfilippo syndrome type A (MPS IIIA). ABO-102 is current...
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilipp...
Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease
Abeona Stock Moves Higher After MPS IIIA Gene Therapy Shows Increase In Brain Volume
Abeona Therapeutics Inc (NASDAQ: ABEO) announced magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A study of ABO-102 gene therapy in Sanfilippo Syndrome Type A (MPS IIIA). Data indicat...
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome ...
New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS and Related Diseases New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS...
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystro...
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical...
Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder
Abeona Therapeutics Inc (NASDAQ: ABEO) has announced updated data from Phase 1/2a trial for up to six years following treatment with EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The da...
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullos...
NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial r...
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
NEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and...
Best Penny Stocks in 2021 So Far? Here's 4 You Should Check Out
These penny stocks are pushing up, should you add them to your watchlist? The post Best Penny Stocks in 2021 So Far?
Abeona Therapeutics Issues Letter to Stockholders
NEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to stockholders in...
Abeona Therapeutics Appoints Head of Research & Clinical Development
NEW YORK and CLEVELAND, May 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas Seshadri,...
Abeona Therapeutics Reports First Quarter Financial Results
Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL™ study
Moving Average Crossover Alert: Abeona Therapeutics (ABEO)
Abeona Therapeutics (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front